centanafadine

Centanafadine is an investigational **oral small-molecule norepinephrine-dopamine-serotonin reuptake inhibitor** being developed primarily by **Otsuka** for **attention-deficit/hyperactivity disorder** in adults, adolescents, and children. It is often described as a **first-in-class NDSRI/triple reuptake inhibitor**, with highest potency at the **norepinephrine transporter**, lower potency at the **dopamine transporter**, and still lower potency at the **serotonin transporter**. Clinical development has focused mainly on **sustained-release tablets or extended-release capsules** given **twice daily**, with phase 2 and phase 3 studies showing efficacy in adult ADHD and positive topline pediatric phase 3 results in children and adolescents with ADHD. Across the cited program, the 400 mg/day sustained-release regimen emerged as a key adult dose based on efficacy and tolerability, with common adverse events including decreased appetite, headache, nausea, dry mouth, diarrhea, and rash. Public materials also indicate development interest beyond ADHD, including **major depressive disorder**.

Brand names

Centanafadine SRCentanafadine XR

Other names

centanafadinecentanafadine sustained-releasecentanafadine SRcentanafadine extended-release